Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Imran Khan and John O'Bryan.
Connection Strength

4.033
  1. Identification of the nucleotide-free state as a therapeutic vulnerability for inhibition of selected oncogenic RAS mutants. Cell Rep. 2022 02 08; 38(6):110322.
    View in: PubMed
    Score: 0.849
  2. Targeting the KRAS a4-a5 allosteric interface inhibits pancreatic cancer tumorigenesis. Small GTPases. 2022 Jan; 13(1):114-127.
    View in: PubMed
    Score: 0.805
  3. Probing RAS Function with Monobodies. Methods Mol Biol. 2021; 2262:281-302.
    View in: PubMed
    Score: 0.787
  4. Therapeutic targeting of RAS: New hope for drugging the "undruggable". Biochim Biophys Acta Mol Cell Res. 2020 02; 1867(2):118570.
    View in: PubMed
    Score: 0.725
  5. Mutations in the a4-a5 allosteric lobe of RAS do not significantly impair RAS signaling or self-association. J Biol Chem. 2022 Nov 02; 102661.
    View in: PubMed
    Score: 0.223
  6. Targeting the "undruggable" RAS with biologics. Adv Cancer Res. 2022; 153:237-266.
    View in: PubMed
    Score: 0.205
  7. Inhibition of RAS: proven and potential vulnerabilities. Biochem Soc Trans. 2020 10 30; 48(5):1831-1841.
    View in: PubMed
    Score: 0.194
  8. Biology, pathology, and therapeutic targeting of RAS. Adv Cancer Res. 2020; 148:69-146.
    View in: PubMed
    Score: 0.190
  9. Ceramide synthase 6 impacts T-cell allogeneic response and graft-versus-host disease through regulating N-RAS/ERK pathway. Leukemia. 2022 07; 36(7):1907-1915.
    View in: PubMed
    Score: 0.054
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.